CANNIBICS PHARMACEUT (CNBX)

1.04+0.01 ( +0.97% ) Jun24

Instant Analysis On Any Stock…

Your Marijuana Trend Report Is Ready!

 

Instant Analysis On Any Stock…

Your Marijuana Trend Report Is Ready!

 

CNBX Detailed Quote

Last Trade: 1.04
Trade Time: 3:59pm
Change: +0.01
Perc Change: +0.97%
Prev Close: 1.03
Open: 1.07
Day's Range: 0.98 - 1.08
Bid: N/A
EPS -0.01
52wk Range: 0.04 - 7.60
Volume: 362719
Avg Vol: 493173
Market Cap: 119.76M
P/E (ttm): N/A
PES (ttm): -0.01
Ask: N/A

CNBX Recent Headlines

  • Cannabics Pharmaceuticals Inc. Provides Shareholders Update June 2017 06/02/2017 01:39 PMCannabis has the potential of being a natural cancer attenuator comprising numerous active compounds which interact with human cells in a complex manner. Understanding the biological mechanism is a long and profound process, yet, utilizing diagnostic lab tests and clinical studies this potential can be unraveled. Cannabics Pharmaceuticals engages in various technologies and studies that together create the knowledge of treating cancer patients with cannabis.
  • Cannabics Pharmaceuticals Raises $3,000,000 in Capital Raise Transaction 05/10/2017 01:10 PMCannabics Pharmaceuticals Inc. (CNBX) today announced it has entered into a securities purchase agreement with D-Beta One EQ, Ltd. ("D-Beta"). D-Beta will purchase 3,000,000 shares of common stock (the "Purchased Shares") at a purchase price of $1.00 per share, for aggregate proceeds of $3.0 million and may purchase up to an additional 1,500,000 shares of common stock (the "Additional Shares") at a purchase price of $2.00 per share over the next 12 months. Pursuant to the Purchase Agreement, Cannabics Pharmaceuticals is required to register all shares previously acquired by D-Beta or its affiliates, the Purchased Shares, and the Additional Shares.
  • Cannabics Pharmaceuticals Announces Scientific Collaboration With A Leading CTC European Lab 05/03/2017 06:14 PMTEL AVIV, Israel, May 3, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) today announced it has begun a scientific collaboration with a medical laboratory in Europe, a world leader in the field of CTC (circulating tumor cells) count and drug sensitivity tests for cancer patients. The blood test results enables practitioners and patients to monitor the number of circulating tumor cells as an indication for cancer characteristics, treatment efficacy and and re-occurrence.
  • Here Are The 5 Stocks Added To The U.S. Marijuana Index 04/12/2017 03:09 PMThe United States Marijuana Index has jumped from a level of 48.39 a year ago to the current level of 70.83, an increase of 46%.
  • Cannabics Pharmaceuticals Inc. Receives the Final Report of Its Research on Antitumor Properties of Cannabinoids Held in Israel 04/03/2017 08:55 PMTEL AVIV, Israel, April 3, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) is pleased to announce that it received the final report of the research held in the Technion Israel Institute of Technology, in which the antitumor activity of cannabinoids was reflected in several types of cancer (breast, ovarian, colon, pancreatic, gastric, glioblastoma). The results which were obtained, using High Throughput Screening technology (HTS), clearly indicate that the company's cannabinoid compounds caused apoptosis (programed cancer cell death) in all cancer types mentioned above with no effect on healthy normal cells. Itamar Borochov, CEO of Cannabics Pharmaceuticals said, "The results from this research strengthen our vision of creating anticancer treatments based on natural cannabis medicine".

FIND OUT HOW MUCH MOMENTUM IS DRIVING YOUR MARIJUANA STOCK!

AS SEEN ON
>>